Abstract
Background
Both nonthyroidal illness syndrome and renal dysfunction are associated with increased mortality risk in acute myocardial infarction (AMI). However, it is unclear whether combined NTIS and renal dysfunction further increase mortality risk. Therefore, our aim is to investigate whether combined NTIS and renal dysfunction further increases mortality risk in patients with acute myocardial infarction (AMI).
Methods
A total of 1295 inpatients with AMI were divided into normal group (n = 692), NTIS group (n = 139), renal dysfunction group (n = 304), and combined NTIS and renal dysfunction group (n = 160). Heart function, in-hospital, all-cause and cardiovascular mortality were compared among the four groups.
Results
After adjustment for age and sex, left ventricular ejection fraction was significantly lower in the combined group (48 ± 11%) than in the NTIS group (52 ± 10%, P = 0.017), the renal dysfunction group (52 ± 10%, P = 0.001) and the normal group (56 ± 8%, P < 0.001). After controlling for confounding factors, compared with the normal group, the NTIS and the renal dysfunction group represented higher risks of in-hospital mortality (OR: 3.643, P = 0.028; OR:3.135, P = 0.042, respectively), all-cause mortality (HR: 2.138, P = 0.007; HR: 2.050, P = 0.003, respectively), and cardiovascular mortality (HR:2.134, P = 0.042; HR:2.237, P = 0.010, respectively). Compared to those in the NTIS and the renal dysfunction group, the patients in the combined group showed a further increased risk for in-hospital mortality (OR:2.916, P = 0.039; OR:2.487, P = 0.036, respectively), all-cause mortality (HR: 1.939, P = 0.015; HR: 2.020, P = 0.002, respectively) and cardiovascular mortality (HR:2.420, P = 0.010; HR:2.303, P = 0.002, respectively).
Conclusions
Both NTIS and renal dysfunction increase short-term in-hospital mortality, and long-term all-cause and cardiovascular mortality risk in patients with AMI. Furthermore, the coexistence of NTIS and renal dysfunction presents further increased mortality risk in AMI patients.
Electronic supplementary material
The online version of this article (10.1186/s12872-019-1027-1) contains supplementary material, which is available to authorized users.
Keywords: Nonthyroidal illness syndrome, Renal insufficiency, Acute myocardial infarction, Cardio-renal-nonthyroidal illness syndrome
Background
Ischemic heart disease will be the foremost cause of morbidity and mortality worldwide [1, 2]. As the first manifestation of ischemic heart disease, acute myocardial infarction (AMI) can cause acute alteration in thyroid function, referred to as “nonthyroidal illness syndrome (NTIS)”, which is characterized by decreased free T3 levels (FT3) with normal or low free thyroxine (FT4) and thyroid-stimulating hormone (TSH) levels [3, 4]. Currently, a growing number of studies have demonstrated that NTIS is an independent predictor of mortality in patients with heart failure and IHD [5–8]. For example, Iervasi et al. [7] reported that patients with NTIS had 1.6 times the risk of cardiovascular mortality than euthyroid patients. Iglesias et al. [9] also found that FT3 was an independent predictor of cardiovascular mortality in patients aged over 65 years.
On the other hand, renal insufficiency has been related to unfavorable performance in patients with AMI, such as increased cardiovascular mortality risk, painless myocardial infarction and various electrolyte disorders [10–12]. For example, the Survival and Ventricular Enlargement (SAVE) Study [13] showed that eGFR < 45 ml/min/1.73 m2 should be particularly considered as a major risk factor for cardiovascular mortality after AMI. Furthermore, Anavekar et al. [12] found that even mild reduced eGFR (below 81 ml/min/1.73 m2) was also closely associated with an increased risk for cardiovascular complications after AMI. Therefore, renal dysfunction is a powerful predictor of cardiovascular events and cardiovascular mortality [14, 15]. Moreover, renal insufficiency is also a pronounced marker of cardiac function and correlates directly with survival in patients with heart disease [16]. The increased cardiovascular mortality in patients with renal insufficiency can be caused by cardio-renal syndrome, which is regarded as disorders of the heart and kidney whereby dysfunction in one organ may induce dysfunction of the other in acute or chronic conditions [17].
Although both renal dysfunction and NTIS have been extensively investigated in AMI, few studies have thoroughly examined their reciprocal relationship in AMI patients. In recent years, the relationship between cardio-renal syndrome and thyroid function causes for concern [18]. Because cardio-renal syndrome is related to increased mortality risk and NTIS may cause the deterioration of both renal and cardiac function [16, 19, 20], we hypothesize that the combination of renal dysfunction and NTIS may cause a steep increase in mortality risk in AMI patients. Therefore, our primary aims are to assess the effect of renal dysfunction and NTIS on cardiac function and mortality risk, and to investigate whether the coexistence of NTIS and renal dysfunction further increases the future mortality risk in AMI.
Methods
From June 2005 to March 2013, 1468 patients with AMI aged 31 to 97 were consecutively enrolled in the Department of Cardiology of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. This observational prospective study got the approval of the ethics committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital and written informed consent was obtained from each participant. The flow chart of enrollment of subjects in this study is presented in Fig. 1. Patients who presented with diseases or underwent medications that affected the measurement of thyroid profile or renal function were excluded from the study.
Fig. 1.
Enrollment and follow-up of subjects
Ultimately, the remaining 1295 patients were included in the present study. NTIS was defined as FT3 level below the lower limit of the reference interval accompanied with FT4 and TSH in or below the reference range [3, 4, 6]. The reference intervals for thyroid function were as follows: FT3 3.1 to 6.8 pmol/l, FT4 12.0 to 22.0 pmol/l, and TSH 0.27 to 4.20 IU/ml. Renal function was evaluated by the estimated glomerular filtration rate (eGFR), which was calculated using the simplified MDRD formula: eGFR =175 × (Serum creatinine)-1.154 × (age)-0.203(× 0.742 if female) [21]. The cut-off value of renal dysfunction was 60 ml/min/1.73 m2.
Patients were divided into four groups based on the diagnosis of NTIS and renal dysfunction: normal group(n = 692), without NTIS and renal dysfunction; NTIS group(n = 139), with NTIS but without renal dysfunction; renal dysfunction group(n = 304), with renal dysfunction but without NTIS; combined group(n = 160), with NTIS and renal dysfunction.
The admitted 1295 subjects were interviewed to obtain their information on sex, age, histories of hypertension and diabetes mellitus, alcohol consumption, smoking habits, and medicine therapy. Physical examinations, including weight, height, and blood pressure, were performed for individuals according to our previous protocols [22–25]. Body mass index (BMI) was calculated as weight divided by height squared. Blood samples were taken for laboratory indicators within 24 h after admission. The laboratory measurements including serum creatinine (SCr), albumin (Alb), total triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), white blood cell count (WBC), hemoglobin (Hb), fasting plasma glucose (FPG), and C-reactive protein (CRP) were determined by standard laboratory protocols. NT-pro B-type natriuretic peptide (NT-pro BNP) and the thyroid function profile, including FT3, FT4, and TSH, were measured using a chemiluminescence technique (Cobas 6000; Roche Diagnostics GmbH, Mannheim, Germany). Coronary angiography was performed by standard Judkins techniques and patients with eGFR< 30 ml/min/1.73 m2 received iodixanol as contrast media and the others received iohexol. All patients received heparin during coronary angiography. Left ventricular ejection fraction (LVEF) was assessed by echocardiography (Acuson Sequoia 512 scanner; Siemens Medical Solutions, Mountain View, CA). Severe acute heart failure was regarded as Killip class>II [26]. Infarct type (NSTEMI vs STEMI), revascularization (percutaneous coronary intervention or coronary artery bypass graft), and in-hospital mortality was determined based on hospitalization records.
After discharge, the patients were followed up for 1 to 8.5 years (median 4 years). The data of overall and cardiovascular death were obtained annually from telephone interviews with patients or their relatives and hospital readmission records. Cardiovascular deaths required the documentation of myocardial infarction, cardiogenic shock, significant arrhythmia, severe heart failure, cerebrovascular events and pulmonary embolism. Sudden unexpected deaths which occurred outside the hospital were classified as cardiovascular deaths. Besides, overall and cardiovascular deaths did not include in-hospital deaths. The flow chart of follow-up of subjects is showed in Fig. 1. Finally, 79 patients (6.5%) were lost at follow-up.
The diagnosis of AMI was consistent with the guidelines of the ACC/AHA for the management of AMI in 1999 and 2007, including a dynamic rise and fall of Creatine-Kinase-MB isoform and Cardiac Troponin together with evidence of myocardial ischaemia [27, 28]. The criteria of hypertension, diabetes mellitus, smoking, and alcohol status were in accordance with description in our previous study [22–25].
The analyses of our data were conducted with SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Normality was checked for continuous variables. Continuous variables were described as means with SDs or expressed as the median and inter-quartile range. One-way ANOVA with LSD or Kruskal-Wallis test were used to compare the differences of normally or non-normally distributed variables. Chi-square test was taken to compare the rates among four groups. Binary logistic regression was used to evaluate differences of categorical variables and to compare odds ratio (OR) of in-hospital mortality in the four groups. Linear regression was used to evaluate differences of continuous variables while controlling for other factors. Adjusted Kaplan-Meier survival curves were performed to estimate all-cause mortality and cardiovascular mortality. Cox proportional hazard regression analysis was applied to estimate hazard ratio (HR) of all-cause and cardiovascular death in the four groups. Three models were constructed: model 1 included adjustments for age, sex, smoking use, alcohol status, hypertension, diabetes mellitus, medical therapy and BMI; model 2 included additional adjustments for LVEF, Killip class, lg(NT-pro BNP) infarct type (NSTEMI vs STEMI) and revascularization; and model 3 had additional adjustment factors encompassing WBC, Hb, Alb, TG, TC, HDL-C,LDL-C, FPG and CRP. We also performed the sensitivity analysis by recalculating eGFR and regrouped which was based on CKD-EPI formula [29]. A P-value of < 0.05 was considered as statistically significant.
Results
Characteristics of study subjects
Enrollment and follow-up of subjects are completed in Fig. 1. The baseline characteristics of study subjects are presented in Table 1. The combined group was associated with higher prevalence of diabetes mellitus, higher WBC and CRP, less revascularization, and lower Hb compared to the NTIS, the renal dysfunction and the normal group after controlling for age and sex (all P < 0.05). In addition, older age, more female patients, higher CRP, higher prevalence of diabetes mellitus, and lower Hb and BMI were found in the NTIS group and the renal dysfunction group than in the normal group after adjustment for age and sex (all P < 0.05).
Table 1.
Clinical characteristics of the study subjects
| Variables | Normal (n = 692) |
NTIS (n = 139) |
Renal dysfunction (n = 304) | Combined (n = 160) | P value | P value* |
|---|---|---|---|---|---|---|
| Age (years) | 65 ± 13 | 70 ± 12 | 75 ± 9 | 77 ± 10 | < 0.001 | < 0.001 |
| Male(n,%) | 536 (77.5%) | 78 (56.1%) | 147 (48.4%) | 97 (60.6%) | < 0.001 | 0.001 |
| Hypertension(n,%) | 403 (58.2%) | 83 (59.7%) | 227 (74.7%) | 107 (66.9%) | < 0.001 | 0.112 |
| Diabetes mellitus (n,%) | 181 (26.2%) | 46 (33.1%) | 111 (36.5%) | 61 (38.1%) | 0.001 | 0.001 |
| Smoking(n,%) | 452 (65.5%) | 82 (59.0%) | 150 (49.3%) | 81 (50.6%) | < 0.001 | 0.083 |
| Alcohol(n,%) | 50 (7.3%) | 5 (3.6%) | 7 (2.3%) | 6 (3.8%) | 0.006 | 0.597 |
| SBP (mmHg) | 128 ± 22 | 123 ± 23 | 132 ± 24 | 127 ± 26 | 0.003 | < 0.001 |
| DBP (mmHg) | 75 ± 13 | 70 ± 13 | 73 ± 13 | 72 ± 14 | 0.001 | < 0.001 |
| BMI (kg/m2) | 24.24 ± 2.04 | 23.36 ± 2.53 | 23.55 ± 2.53 | 23.46 ± 2.66 | < 0.001 | 0.03 |
| WBC (×109/l) | 8.64 ± 3.69 | 9.71 ± 4.90 | 8.30 ± 3.98 | 9.98 ± 4.91 | < 0.001 | < 0.001 |
| Hb (g/l) | 139 ± 15 | 129 ± 16 | 124 ± 17 | 116 ± 20 | < 0.001 | < 0.001 |
| Alb (g/l) | 41 ± 6 | 38 ± 6 | 40 ± 5 | 37 ± 6 | < 0.001 | 0.001 |
| CRP (mg/l) | 3.4 (1.6–6.5) | 10.0 (4.8–21.3) | 5.1 (3.5–8.0) | 18.2 (8.8–33.0) | < 0.001 | < 0.001 |
| TG (mmol/l) | 1.54 ± 0.91 | 1.37 ± 1.07 | 1.40 ± 0.80 | 1.30 ± 0.91 | < 0.001 | 0.005 |
| TC (mmol/l) | 4.60 ± 1.15 | 4.64 ± 1.15 | 4.34 ± 1.14 | 4.24 ± 1.17 | 0.007 | < 0.001 |
| HDL-C(mmol/l) | 1.05 (0.90–1.22) | 1.05 (0.93–1.21) | 1.06 (0.85–1.23) | 1.03 (0.87–1.20) | 0.361 | 0.245 |
| LDL-C(mmol/l) | 2.92 (2.34–3.55) | 2.80 (2.23–3.55) | 2.67 (2.09–3.44) | 2.56 (2.02–3.25) | < 0.001 | 0.547 |
| FPG (mmol/l) | 6.98 ± 3.30 | 7.95 ± 3.65 | 7.10 ± 3.31 | 7.60 ± 3.07 | 0.003 | 0.007 |
| FT3(pmol/l) | 4.05 ± 0.55 | 2.60 ± 0.47 | 3.88 ± 0.53 | 2.52 ± 0.46 | < 0.001 | < 0.001 |
| FT4(pmol/l) | 16.15 ± 2.23 | 15.26 ± 2.06 | 16.52 ± 2.30 | 15.17 ± 2.53 | < 0.001 | < 0.001 |
| TSH(mU/l) | 1.30 (0.75–2.12) | 1.26 (0.57–1.94) | 1.47 (0.98–2.29) | 1.25 (0.59–1.84) | < 0.001 | 0.004 |
| sCr (μmol/l) | 76 (65–88) | 74 (60–89) | 118 (102–142) | 135 (109–178) | < 0.001 | < 0.001 |
| eGFR(ml/min/1.73m2) | 89.69 ± 29.58 | 86.77 ± 28.15 | 44.03 ± 12.90 | 39.84 ± 14.50 | < 0.001 | < 0.001 |
| Antiplatelet agents(n,%) | 446 (64.6%) | 93 (66.9%) | 180 (59.2%) | 96 (60.0%) | 0.241 | 0.491 |
| β-blockers(n,%) | 379 (55.0%) | 77 (55.4%) | 217 (71.4%) | 110 (68.8%) | < 0.001 | 0.005 |
| LLDs (n,%) | 462 (67.0%) | 95 (68.3%) | 158 (52.1%) | 92 (57.5%) | < 0.001 | 0.040 |
| ACEIs/ARBs(n,%) | 363 (52.6%) | 89 (64.0%) | 140 (46.2%) | 70 (43.8%) | 0.001 | 0.133 |
| CCBs (n,%) | 81 (11.7%) | 12 (8.6%) | 39 (12.8%) | 19 (11.9%) | 0.649 | 0.922 |
| Diuretics(n,%) | 492 (71.2%) | 116 (83.5%) | 210 (69.1%) | 114 (71.3%) | 0.014 | 0.873 |
| Revascularization during the present hospitalization(n,%) | 539 (77.9%) | 98 (70.5%) | 163 (53.6%) | 68 (42.5%) | < 0.001 | < 0.001 |
| Prior PCI or CABG (n,%) | 24 (3.5%) | 4 (2.9%) | 6 (2.0%) | 6 (3.8%) | 0.604 | 0.622 |
| Infarct type (NSTEMI n,%) | 42 (6.1%) | 11 (7.9%) | 17 (5.6%) | 12 (7.5%) | 0.725 | 0.627 |
Values are expressed as mean ± SD,median with interquartile range or percentages
The p values were not adjusted for age and sex for the trend
The p values* were adjusted for age and sex for the trend
Revascularization included percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG)
Comparison of cardiac function among the four groups
As apparent from Fig. 2a, LVEF was significantly lower in the patients with combined NTIS and renal dysfunction (48 ± 11%) than in the patients with either NTIS (52 ± 10%, P = 0.017) or renal dysfunction (52 ± 10%, P = 0.001) and in the patients with normal FT3 and normal renal function (56 ± 8%, P < 0.001) after adjustment for age and sex (Fig. 2a). In addition, the percentage of Killip class>II in the combined group (39.4%) was markedly higher than that in the NTIS (21.6%, P = 0.008) and the renal dysfunction group (28.3%, P = 0.022) and that in the normal group (11.9%, P < 0.001) after controlling for age and gender variables (Fig. 2b). Furthermore, participants in the combined group had an obviously higher level of NT-pro BNP than participants in the NTIS group, the renal dysfunction group, and the normal group (Fig. 2c).
Fig. 2.
Comparison of cardiac function among the four groups at baseline. (a) Mean LVEF (%) among the four groups. (b) The percentage of Killip class>II (%) among the four groups. (c) Median NT-pro BNP (ng/l) among the four groups
Comparison of mortality rate among the four groups
The comparison of mortality rate in the four groups is demonstrated in Fig. 3. In-hospital mortality was 21.9% in the patients with combined NTIS and renal dysfunction, which was significantly higher than that in the NTIS group (10.3%, P = 0.034), the renal dysfunction group (7.6%, P < 0.001), and the normal group (1.4%, P < 0.001) (Fig. 3a). During a median follow-up of 4 years, 213 patients died, which included 130 patients due to cardiovascular causes. Similar to in-hospital mortality, all-cause mortality and cardiovascular mortality in the combined group were 39.1 and 27.8%, respectively, which were also significantly higher than in the NTIS group (24.3%, P = 0.038; 13.0%, P = 0.020, respectively), the renal dysfunction group (21.7%, P < 0.001; 13.5%, P = 0.001, respectively) and the normal group (12.9%, P < 0.001; 7.4%, P < 0.001, respectively) (Fig. 3b and Fig. 3c).
Fig. 3.
Comparison of in-hospital, all-cause and cardiovascular mortality among the four groups. (a) In-hospital mortality among the four groups. (b) All-cause mortality among the four groups. (c) Cardiovascular mortality among the four groups. Overall and cardiovascular mortality did not include in-hospital mortality
Comparison of mortality risk among the four groups
A binary logistic regression analysis associated with in-hospital mortality is shown in Table 2. When the normal group was considered as reference, the combined group, the NTIS group, and the renal dysfunction group showed an obviously increased risk for in-hospital death(OR: 7.798, 95% CI: 2.722 to 22.339, P < 0.001; OR: 3.643, 95% CI: 1.154 to 11.505, P = 0.028; and OR: 3.135, 95% CI: 1.043 to 9.422, P = 0.042, respectively). Compared to those in the NTIS and the renal dysfunction group, the patients with combined NTIS and renal dysfunction also showed an increased risk for in-hospital mortality (OR: 2.916, 95% CI: 1.054 to 8.066, P = 0.039 versus NTIS group; OR: 2.487, 95% CI: 1.064 to 5.816, P = 0.036 versus renal dysfunction group, respectively).
Table 2.
Comparison of Odds Ratio of in-hospital mortality
| Normal Group | NTIS Group | Renal dysfunction Group | Combined Group | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR | 95% CI | P value | OR | 95% CI | P value | OR | 95% CI | P value | |
| Model 1 | 1 | 7.034 | 3.019–16.386 | < 0.001 | 4.155 | 1.889–9.141 | < 0.001 | 14.065 | 6.469–30.578 | < 0.001 |
| Model 2 | 1 | 4.256 | 1.383–13.096 | 0.012 | 5.445 | 2.023–14.657 | 0.001 | 7.778 | 2.688–22.508 | < 0.001 |
| Model 3 | 1 | 3.643 | 1.154–11.505 | 0.028 | 3.135 | 1.043–9.422 | 0.042 | 7.798 | 2.722–22.339 | < 0.001 |
Model1: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy (use of antiplatelet agents, β-Blockers, LLDs, ACEIs/ARBs, CCBs, and Diuretics), and BMI (for all patients)
Model2: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy, BMI, LVEF, Killip class, lg(NT-pro BNP), infarct type (NSTEMI vs STEMI), prior PCI or CABG and revascularization (PCI, CABG) (for all patients)
Model3: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy, BMI, LVEF, Killip class, lg(NT-pro BNP), infarct type (NSTEMI vs STEMI), prior PCI or CABG and revascularization (PCI, CABG), WBC, Hb, Alb, TC, TG, HDL-c, LDL-c, FPG and CRP (for all patients)
A Cox proportional hazard regression analysis associated with long-term all-cause and cardiovascular mortality is shown in Table 3. Compared to the normal group, the combined group had 4.140 times the risk of all-cause mortality (95% CI: 2.534 to 6.764; P < 0.001); the NTIS group had 2.138 times (95% CI: 1.234 to 3.704; P = 0.007) and the renal dysfunction group had 2.050 times the risk of overall mortality (95% CI: 1.271 to 3.307; P = 0.003). The combined group, the NITS group and the renal dysfunction group had also an increased risk of cardiovascular mortality compared with the normal group (HR: 5.152, 95% CI: 2.786 to 9.527, P < 0.001; HR: 2.134, 95% CI: 1.028 to 4.430, P = 0.042; HR: 2.237, 95% CI: 1.210 to 4.135, P = 0.010, respectively). In addition, compared with the NTIS group and the renal dysfunction group, the combined group represented a higher risk of all-cause mortality (HR: 1.939, 95% CI: 1.139 to 3.304, P = 0.015 versus NTIS group; HR: 2.020, 95% CI: 1.300 to 3.140, P = 0.002 versus renal dysfunction group, respectively) and cardiovascular mortality (HR: 2.420, 95% CI: 1.239 to 4.725, P = 0.010 versus NTIS group; HR: 2.303, 95% CI: 1.373 to 3.862, P = 0.002 versus renal dysfunction group, respectively). The adjusted Kaplan-Meier curves demonstrated that overall survival and cardiovascular death-free survival in the patients with combined NTIS and renal dysfunction were obviously lower than those in the NTIS group, the renal dysfunction group, and the normal group (all P < 0.05) (Fig. 4).
Table 3.
Comparison of Hazard Ratio of all-cause and cardiovascular mortality
| Normal Group | NTIS Group | Renal dysfunction Group | Combined Group | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
| All-cause mortality | ||||||||||
| Model 1 | 1 | 1.912 | 1.219–2.998 | 0.005 | 1.514 | 1.056–2.170 | 0.024 | 3.209 | 2.157–4.774 | < 0.001 |
| Model 2 | 1 | 2.036 | 1.252–3.312 | 0.004 | 1.675 | 1.090–2.572 | 0.019 | 3.488 | 2.223–5.471 | < 0.001 |
| Model 3 | 1 | 2.138 | 1.234–3.704 | 0.007 | 2.050 | 1.271–3.307 | 0.003 | 4.140 | 2.534–6.764 | < 0.001 |
| Cardiovascular mortality | ||||||||||
| Model 1 | 1 | 1.903 | 1.010–3.587 | 0.047 | 1.730 | 1.074–2.788 | 0.024 | 3.955 | 2.387–6.553 | < 0.001 |
| Model 2 | 1 | 2.141 | 1.087–4.217 | 0.028 | 2.089 | 1.185–3.684 | 0.011 | 4.580 | 2.578–8.136 | < 0.001 |
| Model 3 | 1 | 2.134 | 1.028–4.430 | 0.042 | 2.237 | 1.210–4.135 | 0.010 | 5.152 | 2.786–9.527 | < 0.001 |
Model1: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy (use of antiplatelet agents, β-Blockers, LLDs, ACEIs/ARBs, CCBs, and Diuretics), and BMI (for all patients)
Model2: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy, BMI, LVEF, Killip class, lg(NT-pro BNP), infarct type (NSTEMI vs STEMI), prior PCI or CABG and revascularization (PCI, CABG) (for all patients)
Model3: Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes, medical therapy, BMI, LVEF, Killip class, lg(NT-pro BNP), infarct type (NSTEMI vs STEMI), prior PCI or CABG and revascularization (PCI, CABG), WBC, Hb, Alb, TC, TG, HDL-c, LDL-c, FPG and CRP (for all patients)
Fig. 4.
Adjusted Kaplan-Meier survival curves among the four groups. (a) Adjusted Kaplan-Meier overall survival curves. (b) Adjusted Kaplan-Meier cardiovascular death-free survival curves. Adjusted for age, sex, smoking use, alcohol status, hypertension, diabetes mellitus, medical therapy (use of antiplatelet agents, β-Blockers, LLDs, ACEIs/ARBs, CCBs, and Diuretics), and BMI
The sensitivity analysis showed that the combined renal dysfunction (eGFR was calculated with CKD-EPI formula) and NTIS also further increased in-hospital mortality(OR: 7.139, 95% CI: 2.554 to 19.954, P < 0.001 versus normal group; OR: 2.637, 95% CI: 0.993 to 7.003, P = 0.052 versus NTIS group; OR: 3.178, 95% CI: 1.327 to 7.609, P = 0.009 versus renal dysfunction group, respectively), all-cause mortality(HR: 3.616, 95% CI: 2.172 to 6.021, P < 0.001 versus normal group; HR: 1.817, 95% CI: 1.071 to 3.084, P = 0.027 versus NTIS group; HR: 1.916, 95% CI: 1.180 to 3.109, P = 0.009 versus renal dysfunction group, respectively) and cardiovascular mortality(HR: 4.790, 95% CI: 2.539 to 9.036, P < 0.001 versus normal group; HR: 2.425, 95% CI: 1.071 to 3.084, P = 0. 010 versus NTIS group; HR: 2.118, 95% CI: 1.244 to 3.608, P = 0. 006 versus renal dysfunction group, respectively) (Additional file 1: Table 1 and Additional file 2: Table 2).
Discussion
Despite some controversy, both NTIS and renal dysfunction levels were widely considered to be associated with increased mortality risk in AMI patients. Most studies have supported the long-term prognostic role of NTIS and renal dysfunction in AMI [8, 12, 13, 15]. It is well-known that NTIS is associated with increased inflammatory burden and vascular resistance, and decreases heart rate as well as cardiac contractility, which reduce cardiac output and further accelerate the progression of ischemic heart disease [1, 18, 30, 31]. Altay et al. [32] also indicated that inflammatory status of the upper normal TSH tertile correlated negatively with FT3 in women may mediate mortality or nonfatal cardiac events rather than the action of thyroid hormone. Therefore, NTIS has been suggested to be associated with increased overall and cardiovascular death [5–9]. Similarly, glomerular hyperfiltration is associated with autoimmune activation and low-grade inflammation, leading to chronic diseases like ischemic heart disease [33]. Renal dysfunction has also been related to dyslipidemia, atherosclerosis, arterial calcification and cardiac dysfunction in the progression of inflammation [14, 16, 30]. It was suggested that patients with severe renal insufficiency had 8 times the risk of cardiovascular mortality compared with general population [34]. Consistent with these studies, our findings also showed that both NTIS and renal dysfunction were closely associated with increased mortality risk in AMI patients. Compared with the patients in the normal group, the patients with NTIS had nearly 3.6-, 2.1- and 2.1- fold risk of in-hospital, all-cause and cardiovascular mortality, respectively. Similarly, the patients with renal dysfunction had also obviously increased mortality risk.
However, it has not been investigated so far whether the coexistence of NTIS and renal dysfunction further increases mortality risk in patients with AMI. Therefore, we investigated the prognostic role of combined NTIS and renal dysfunction in AMI. The present findings verified our hypothesis that the patients with combined NTIS and renal dysfunction had a significantly reduced cardiac function and poorer prognosis with significantly increased mortality risk compared with the other three groups. Although only 12.4% of the AMI patients had combined NTIS and renal dysfunction, it accounted for almost half of all deaths within follow-up periods.
Therefore, it is evident that there exists a close association between thyroid and renal function. Thyroid hormone alterations are often seen with the worsening of kidney function. Pathophysiological factors caused by renal insufficiency contribute to the development of NTIS. The kidney is associated with the metabolism and excretion of thyroid hormone [35]. Renal insufficiency-related metabolic disorders such as consumption of various proteins, metabolic acidosis, anemia and iodide retention inhibit the forming, releasing and converting of thyroid hormone, which is strongly associated with the presence of NTIS [18]. It was found that NTIS state was present in more than 75% of individuals with end-stage renal disease [18, 20]. Furthermore, Song et al. [20] reported that T3 levels were positively associated with eGFR levels. On the other hand, thyroid hormone also plays an important role in preserving normal renal function. Thus, NTIS can also result in deterioration of renal function via several pathways including renal hypoperfusion resulted from worsening cardiac output, activation of the renin angiotensin and aldosterone pathways (RAAS), reduction of systemic levels of vasodilators and decrease of reabsorption of sodium and water [18]. The fact in this study that NTIS was more frequently detected in patients with renal dysfunction than preserved renal function, and renal dysfunction was more common in patients with thyroid dysfunction than normal thyroid profile supported the close association between thyroid hormone and renal function.
Furthermore, it is suggested that NTIS and renal dysfunction contribute to the deterioration of cardiac function. Studies reported that NTIS caused deterioration of cardiac function early after AMI and further ventricular remodeling, as well as arrhythmia, vasoconstriction, dyslipidemia, and vascular calcification [1, 18, 19]. It was reported that NTIS was associated with lower LVEF and cardiac index [5, 19]. Likewise, renal functional impairment contributed to the progression of left ventricular hypertrophy, increase in cardiac filling pressures and progressive ventricular dilation by sodium and water retention [16, 36]. It was found 85% of patients with end-stage renal disease having abnormal left ventricular structure and function [36]. Consistent with these findings, we also found that compared with those with normal thyroid and renal function, the patients with either NTIS or renal dysfunction had significantly poorer cardiac function, such as lower LVEF and higher NT-pro BNP.
More importantly, the combination of NTIS and renal dysfunction further aggravates heart function, and increases mortality risk in AMI patients in the present study. The fact that NTIS is associated with lower LVEF in patients with renal insufficiency may also implicate the combined adverse effect of NTIS and renal dysfunction on heart function [37]. The interactions between NTIS and renal dysfunction cause deterioration of cardiac function. We found that the patients with combined NTIS and renal dysfunction had markedly lower LVEF, higher percentage of Killip class>IIand higher NT-pro BNP levels than the patients with NTIS and the patients with renal dysfunction. It implied that combined NTIS and renal dysfunction was associated with more serious deterioration of cardiac function than either NTIS or renal dysfunction in AMI patients. More importantly, the combination of NTIS and renal dysfunction strongly predicted short term in-hospital mortality, long term all-cause and cardiovascular mortality in AMI, which were far in excess of that observed AMI patients with either NTIS or renal dysfunction alone. Therefore, our findings may verify that the combination of NTIS and renal dysfunction is a strong independent predictor of mortality in patients with AMI, exceeding either isolated NTIS or isolated renal dysfunction, possibly through the deterioration of cardiac function. Our findings suggest that in AMI patients, renal dysfunction and nonthyroidal illness syndrome represent a combination of disease progression. NTIS and kidney dysfunction may mutually amplify their respective impacts on overall and cardiovascular mortality in AMI, which cause a synergistic action and finally remarkably increase mortality risks in patients with AMI. Meanwhile, cardiac ischemia and dysfunction may cause progression of renal failure and presence of NTIS [1, 16, 18, 38]. Worsening renal function was common in heart failure patients in the post-MI period [38, 39]. Therefore, NTIS, renal dysfunction, and reduced heart function may form a vicious circle in AMI, which lead to a further increase of mortality.
Some limitations should be acknowledged. First, this is a single-center cohort study, in which basal characteristics of groups is not equal. However, we have controlled these confounding factors as much as possible in the present analyses. Despite the inherent design limitations, patients in observational studies better represent those seen in clinical practice. In addition, the present study lacks data of follow-up thyroid and renal function tests. Moreover, with 6.4% of total patients lost to follow up, data on the endpoint outcome is not totally complete. The date range of enrollment is extended in order to increase the sample size and Cox proportional hazard regression analyses have been applied to reduce bias. A far larger multi-center prospective cohort study should be carried out to verify our findings in AMI population and other populations.
Conclusions
The present findings suggest that both NTIS and renal dysfunction increase short-term in-hospital mortality, and long-term all-cause and cardiovascular mortality risk in patients with AMI. Furthermore, the coexistence of NTIS and renal dysfunction presents further reduced heart function, and predicts further increased mortality risk in patients with AMI.
Additional files
Table S1. Comparison of Odds Ratio of in-hospital mortality when eGFR was calculated with CKD-EPI formula. (DOC 32 kb)
Table S2. Comparison of Hazard Ratio of all-cause and cardiovascular mortality when eGFR was calculated with CKD-EPI formula. (DOCX 20 kb)
Acknowledgements
Not applicable
Funding
This work was funded by the National Key Research and Development Plan (2018YFC1314905), the National Natural Science Foundation of China (81170759, 81770813) and the Science and Technology Commission of Shanghai Municipality (15411960600).
Availability of data and materials
Data for this analysis were obtained from the Department of Cardiology of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. The dataset of this article is accessible on reasonable request from the corresponding author.
Abbreviations
- ACEIs
Angiotensin-Converting Enzyme Inhibitors
- Alb
Albumin
- AMI
Acute Myocardial Infarction
- ARBs
Angiotensin Receptor Blockers
- BMI
Body Mass Index
- CABG
Coronary Artery Bypass Graft
- CCBs
Calcium Channel Blockers
- CRP
C-reactive Protein
- DBP
Diastolic Blood Pressure
- eGFR
Estimated Glomerular Filtration Rate
- FPG
Fasting Plasma Glucose
- FT3
Free Triiodothyronine
- FT4
Free Thyroxine
- Hb
Hemoglobin
- HDL-C
High Density Lipoproteins Cholesterol
- LDL-C
Lower Density Lipoproteins Cholesterol
- LLDs
Lipid-Lowering Drugs
- LVEF
Left Ventricular Ejection Fraction
- NSTEMI
Non ST-segment Elevation Myocardial Infarction
- NTIS
Nonthyroidal Illness Syndrome
- NT-Pro BNP
N-terminal Pro-brain Natriuretic Peptide
- PCI
Percutaneous Coronary Intervention
- SBP
Systolic Blood Pressure
- sCr
Serum Creatinine
- STEMI
ST-segment Elevation Myocardial Infarction
- TC
Total Cholesterol
- TG
Total Triglyceride
- TSH
Thyroid-Stimulating Hormone
- WBC
White Blood Cell
Authors’ contributions
LXL and MW provided the hypothesis, revised the manuscript, and handled funding and supervision. JWW, YR, ZGL, JG, CCZ collected and analyzed the data. JWW and LXL drafted the manuscript. LXL, JWW, ZGL, YR, and MW participated in the revision of manuscript. All authors approved the final version to be published.
Ethics approval and consent to participate
This observational prospective study got the approval of the ethics committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital and written informed consent was obtained from each participant.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Jun-Wei Wang, Email: wangjunwei0611@163.com.
Ying Ren, Email: renying@sjtu.edu.cn.
Zhi-Gang Lu, Email: zhigang.lu@medmail.com.cn.
Jing Gao, Email: harry_0213@163.com.
Cui-Chun Zhao, Email: zccmagic@hotmail.com.
Lian-Xi Li, Phone: +86 21 64369181 58570, Email: lilx@sjtu.edu.cn.
Meng Wei, Phone: + 86 21 64369181 58332, Email: mrrweei@medmail.cn.
References
- 1.Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122(4):385–393. doi: 10.1161/CIRCULATIONAHA.109.917922. [DOI] [PubMed] [Google Scholar]
- 2.He J, Gu D, Wu X, Reynolds K, Duan X, Yao C, Wang J, Chen CS, Chen J, Wildman RP, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124–1134. doi: 10.1056/NEJMsa050467. [DOI] [PubMed] [Google Scholar]
- 3.McIver B, Gorman CA. Euthyroid sick syndrome: an overview. Thyroid. 1997;7(1):125–132. doi: 10.1089/thy.1997.7.125. [DOI] [PubMed] [Google Scholar]
- 4.Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012; 22(12):1200–1235. [DOI] [PubMed]
- 5.Opasich C, Pacini F, Ambrosino N, Riccardi PG, Febo O, Ferrari R, Cobelli F, Tavazzi L. Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur Heart J. 1996;17(12):1860–1866. doi: 10.1093/oxfordjournals.eurheartj.a014804. [DOI] [PubMed] [Google Scholar]
- 6.Iervasi G, Pingitore A, Landi P, Raciti M, Ripoli A, Scarlattini M, L'Abbate A, Donato L. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation. 2003;107(5):708–713. doi: 10.1161/01.cir.0000048124.64204.3f. [DOI] [PubMed] [Google Scholar]
- 7.Iervasi G, Molinaro S, Landi P, Taddei MC, Galli E, Mariani F, L'Abbate A, Pingitore A. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167(14):1526–1532. doi: 10.1001/archinte.167.14.1526. [DOI] [PubMed] [Google Scholar]
- 8.Lazzeri C, Sori A, Picariello C, Chiostri M, Gensini GF, Valente S. Nonthyroidal illness syndrome in ST-elevation myocardial infarction treated with mechanical revascularization. Int J Cardiol. 2012;158(1):103–104. doi: 10.1016/j.ijcard.2012.03.100. [DOI] [PubMed] [Google Scholar]
- 9.Iglesias P, Ridruejo E, Munoz A, Prado F, Macias MC, Guerrero MT, Tajada P, Garcia-Arevalo C, Diez JJ. Thyroid function tests and mortality in aged hospitalized patients: a 7-year prospective observational study. J Clin Endocrinol Metab. 2013;98(12):4683–4690. doi: 10.1210/jc.2012-3849. [DOI] [PubMed] [Google Scholar]
- 10.Choi JS, Kim CS, Bae EH, Ma SK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Kim SW. Suboptimal medical care of patients with ST-elevation myocardial infarction and renal insufficiency: results from the Korea acute myocardial infarction registry. BMC Nephrol. 2012;13:110. doi: 10.1186/1471-2369-13-110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Aronson D, Darawsha W, Promyslovsky M, Kaplan M, Abassi Z, Makhoul BF, Goldberg A, Azzam ZS. Hyponatraemia predicts the acute (type 1) cardio-renal syndrome. Eur J Heart Fail. 2014;16(1):49–55. doi: 10.1093/eurjhf/hft123. [DOI] [PubMed] [Google Scholar]
- 12.Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–1295. doi: 10.1056/NEJMoa041365. [DOI] [PubMed] [Google Scholar]
- 13.Tokmakova MP, Skali H, Kenchaiah S, Braunwald E, Rouleau JL, Packer M, Chertow GM, Moye LA, Pfeffer MA, Solomon SD. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation. 2004;110(24):3667–3673. doi: 10.1161/01.CIR.0000149806.01354.BF. [DOI] [PubMed] [Google Scholar]
- 14.Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203–210. doi: 10.1161/01.cir.102.2.203. [DOI] [PubMed] [Google Scholar]
- 15.Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455–469. doi: 10.1093/eurheartj/eht386. [DOI] [PubMed] [Google Scholar]
- 16.Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome--current understanding and future perspectives. Nat Rev Nephrol. 2014;10(1):48–55. doi: 10.1038/nrneph.2013.250. [DOI] [PubMed] [Google Scholar]
- 17.Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31(6):703–711. doi: 10.1093/eurheartj/ehp507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Meuwese CL, Dekkers OM, Stenvinkel P, Dekker FW, Carrero JJ. Nonthyroidal illness and the cardiorenal syndrome. Nat Rev Nephrol. 2013;9(10):599–609. doi: 10.1038/nrneph.2013.170. [DOI] [PubMed] [Google Scholar]
- 19.Lymvaios I, Mourouzis I, Cokkinos DV, Dimopoulos MA, Toumanidis ST, Pantos C. Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association? Eur J Endocrinol. 2011;165(1):107–114. doi: 10.1530/EJE-11-0062. [DOI] [PubMed] [Google Scholar]
- 20.Song SH, Kwak IS, Lee DW, Kang YH, Seong EY, Park JS. The prevalence of low triiodothyronine according to the stage of chronic kidney disease in subjects with a normal thyroid-stimulating hormone. Nephrol Dial Transplant. 2009;24(5):1534–1538. doi: 10.1093/ndt/gfn682. [DOI] [PubMed] [Google Scholar]
- 21.Levey AS, Stevens LA, Schmid CH, Zhang YL, Rd CA, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604–612. [DOI] [PMC free article] [PubMed]
- 22.Li LX, Li MF, Lu JX, Jia LL, Zhang R, Zhao CC, Ren Y, Tu YF, Shen Y, Liu F, et al. Retinal microvascular abnormalities are associated with early carotid atherosclerotic lesions in hospitalized Chinese patients with type 2 diabetes mellitus. J Diabetes Complicat. 2014;28(3):378–385. doi: 10.1016/j.jdiacomp.2014.02.004. [DOI] [PubMed] [Google Scholar]
- 23.Li LX, Wang AP, Zhang R, Li TT, Wang JW, Bao YQ, Jia WP. Decreased urine uric acid excretion is an independent risk factor for chronic kidney disease but not for carotid atherosclerosis in hospital-based patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2015;14:36. doi: 10.1186/s12933-015-0199-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Li MF, Ren Y, Zhao CC, Zhang R, Li LX, Liu F, Lu JX, Tu YF, Zhao WJ, Bao YQ, et al. Prevalence and clinical characteristics of lower limb atherosclerotic lesions in newly diagnosed patients with ketosis-onset diabetes: a cross-sectional study. Diabetol Metab Syndr. 2014;6:71. doi: 10.1186/1758-5996-6-71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Li LX, Dong XH, Li MF, Zhang R, Li TT, Shen J, Shen J, Bao YQ, Jia WP. Serum uric acid levels are associated with hypertension and metabolic syndrome but not atherosclerosis in Chinese inpatients with type 2 diabetes. J Hypertens. 2015;33(3):482–490. doi: 10.1097/HJH.0000000000000417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384–416. doi: 10.1093/eurheartj/ehi044. [DOI] [PubMed] [Google Scholar]
- 27.Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith ER, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34(3):890–911. [DOI] [PubMed]
- 28.Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, et al. Universal definition of myocardial infarction. Circulation. 2007; 116(22):2634–2653. [DOI] [PubMed]
- 29.Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29. doi: 10.1056/NEJMoa1114248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Tatar E, Kircelli F, Ok E. The contribution of thyroid dysfunction on cardiovascular disease in patients with chronic kidney disease. Atherosclerosis. 2013;227(1):26–31. doi: 10.1016/j.atherosclerosis.2012.10.068. [DOI] [PubMed] [Google Scholar]
- 31.Epstein FH, Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. New Engl J Med 2001; 344(7):501–509. [DOI] [PubMed]
- 32.Altay S, Onat A, Can G, Tusun E, Simsek B, Kaya A. High-normal thyroid-stimulating hormone in euthyroid subjects is associated with risk of mortality and composite disease endpoint only in women. Arch Med Sci. 2018;14(6):1394–1403. doi: 10.5114/aoms.2016.63264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Altay S, Onat A, Ozpamuk-Karadeniz F, Karadeniz Y, Kemaloglu-Oz T, Can G: renal "hyperfiltrators" are at elevated risk of death and chronic diseases. BMC Nephrol 2014, 15:160. [DOI] [PMC free article] [PubMed]
- 34.de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782–1789. doi: 10.1001/jama.2009.1488. [DOI] [PubMed] [Google Scholar]
- 35.Larsen PR. Decade in review-thyroid disease: the endocrinology of thyroid disease from 2005 to 2015. Nat Rev Endocrinol. 2015;11(11):634–636. doi: 10.1038/nrendo.2015.169. [DOI] [PubMed] [Google Scholar]
- 36.Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease effects on the cardiovascular system. Circulation. 2007;116(1):85–97. doi: 10.1161/CIRCULATIONAHA.106.678342. [DOI] [PubMed] [Google Scholar]
- 37.Meuwese CL, Dekker FW, Lindholm B, Qureshi AR, Heimburger O, Barany P, Stenvinkel P, Carrero JJ. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2012;7(1):131–138. doi: 10.2215/CJN.05250511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006;17(10):2886–2891. doi: 10.1681/ASN.2006010063. [DOI] [PubMed] [Google Scholar]
- 39.Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation. 2003;108(22):2769–2775. doi: 10.1161/01.CIR.0000103623.63687.21. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Table S1. Comparison of Odds Ratio of in-hospital mortality when eGFR was calculated with CKD-EPI formula. (DOC 32 kb)
Table S2. Comparison of Hazard Ratio of all-cause and cardiovascular mortality when eGFR was calculated with CKD-EPI formula. (DOCX 20 kb)
Data Availability Statement
Data for this analysis were obtained from the Department of Cardiology of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. The dataset of this article is accessible on reasonable request from the corresponding author.